Editorial

. 2024 May;33(5):547-552.

doi: 10.1016/j.hlc.2024.05.002.

Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction

Paul D Geenty¹, Ann T Gregory², Mark Nolan³, A Robert Denniss⁴, Salvatore Pepe⁵, Aaron L Sverdlov⁶, Liza Thomas⁷

Affiliations

¹ Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, The University of Sydney, NSW, Australia.
² Heart, Lung and Circulation, Sydney, NSW, Australia.
³ Baker Heart and Diabetes Institute, Melbourne, Vic, Australia; Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
⁴ Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Heart, Lung and Circulation, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Department of Cardiology, Blacktown Hospital, and Western Sydney University, Sydney, NSW, Australia.
⁵ Heart, Lung and Circulation, Sydney, NSW, Australia; Heart Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne; Department of Paediatrics, The University of Melbourne, Melbourne, Vic, Australia.
⁶ Newcastle Centre of Excellence in Cardio-Oncology, The University of Newcastle; Hunter Medical Research Institute; Calvary Mater Newcastle, Hunter New England Health, Newcastle, NSW, Australia; Cardiovascular Department, John Hunter Hospital, Newcastle, NSW, Australia. Electronic address: aaron.sverdlov@newcastle.edu.au.
⁷ Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, The University of Sydney, NSW, Australia; Southwest Clinical School, University of New South Wales, NSW, Australia. Electronic address: liza.thomas@sydney.edu.au.

PMID: 38823894
DOI: 10.1016/j.hlc.2024.05.002

Editorial

Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction

Paul D Geenty et al. Heart Lung Circ. 2024 May.

. 2024 May;33(5):547-552.

doi: 10.1016/j.hlc.2024.05.002.

Authors

Paul D Geenty¹, Ann T Gregory², Mark Nolan³, A Robert Denniss⁴, Salvatore Pepe⁵, Aaron L Sverdlov⁶, Liza Thomas⁷

Affiliations

¹ Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, The University of Sydney, NSW, Australia.
² Heart, Lung and Circulation, Sydney, NSW, Australia.
³ Baker Heart and Diabetes Institute, Melbourne, Vic, Australia; Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
⁴ Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Heart, Lung and Circulation, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Department of Cardiology, Blacktown Hospital, and Western Sydney University, Sydney, NSW, Australia.
⁵ Heart, Lung and Circulation, Sydney, NSW, Australia; Heart Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne; Department of Paediatrics, The University of Melbourne, Melbourne, Vic, Australia.
⁶ Newcastle Centre of Excellence in Cardio-Oncology, The University of Newcastle; Hunter Medical Research Institute; Calvary Mater Newcastle, Hunter New England Health, Newcastle, NSW, Australia; Cardiovascular Department, John Hunter Hospital, Newcastle, NSW, Australia. Electronic address: aaron.sverdlov@newcastle.edu.au.
⁷ Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia; Westmead Clinical School, The University of Sydney, NSW, Australia; Southwest Clinical School, University of New South Wales, NSW, Australia. Electronic address: liza.thomas@sydney.edu.au.

PMID: 38823894
DOI: 10.1016/j.hlc.2024.05.002

No abstract available

Keywords: Cardio-Oncology; Cardiology; Cardiovascular disease; Cardiovascular toxicity; Oncology; Risk management.

PubMed Disclaimer

Conflict of interest statement

Disclosures ALS is supported by the National Heart Foundation of Australia Future Leader Fellowship (award ID 106025). ALS has received research grants from Novartis, RACE Oncology and Bristol Myers Squibb; and speaker fees from Novartis, AstraZeneca and Janssen. There are no other relevant author disclosures.

Cited by

Surprising Cardiac Magnetic Resonance Imaging Findings: Rapidly Developing Intracardiac Thrombus with Endomyocardial Fibrosis.
Bulburu İB, Gürdoğan M, Ustabaşıoğlu FE, Yalta K. Bulburu İB, et al. Arq Bras Cardiol. 2025 Aug 4;122(6):e20250030. doi: 10.36660/abc.20250030. eCollection 2025. Arq Bras Cardiol. 2025. PMID: 40767681 Free PMC article. English, Portuguese. No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction

Affiliations

Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources